Key Takeaways
- •In spring 2025, Swiss peptide and oligonucleotide specialist Bachem Holding AG reaffirmed its 2024 outlook and reiterated medium-term growth and margin targets during investor communications.
- •The company’s focus on peptides and oligonucleotides places it in a niche but rapidly evolving segment of the life-sciences industry.
- •Bachem’s core business centers on developing and manufacturing active pharmaceutical ingredients (APIs) and research tools based on peptides and small molecules.
Bachem Holding AG: A Deep Dive into the Peptide CDMO’s Strategy and Market Position
In spring 2025, Swiss peptide and oligonucleotide specialist Bachem Holding AG reaffirmed its 2024 outlook and reiterated medium-term growth and margin targets during investor communications. This update, published on the company’s website and covered by financial media in early 2026, has drawn renewed attention from investors tracking the contract development and manufacturing organization (CDMO) space. Headquartered in Switzerland and listed on the SIX Swiss Exchange under ticker BANB, Bachem operates at the intersection of complex chemistry and pharmaceutical supply chains, serving clients across Europe, North America, and Asia.
The company’s focus on peptides and oligonucleotides places it in a niche but rapidly evolving segment of the life-sciences industry. Peptides, short chains of amino acids, have gained prominence as therapeutic agents due to their high target specificity and relatively low toxicity profiles. Oligonucleotides, including antisense and RNA-based molecules, represent a newer class of advanced therapies that modulate gene expression. Together, these modalities are driving demand for specialized manufacturing capabilities that few CDMOs can provide.
Core Business Model: From Research to Commercial Scale
Bachem’s core business centers on developing and manufacturing active pharmaceutical ingredients (APIs) and research tools based on peptides and small molecules. The company operates as a CDMO, meaning it contracts with biotech and pharmaceutical firms to handle complex chemical synthesis steps that those firms prefer to outsource. This model combines long-term supply agreements with innovation-driven project work. Once a molecule receives regulatory approval, switching suppliers becomes costly and difficult, creating relatively high customer lock-in.
The company provides services across the entire drug development value chain, from early research quantities to full commercial-scale manufacturing. In drug development, peptides are particularly useful for metabolic diseases, oncology, and rare diseases, where their high specificity allows for targeted therapies with fewer off-target effects. Bachem’s capabilities include process development, scale-up, and regulatory support around Good Manufacturing Practice (GMP), which is essential for gaining pharmaceutical approvals. This integrated setup positions Bachem as a strategic partner rather than a mere commodity supplier.
In addition to custom manufacturing, Bachem maintains a catalog business offering a broad portfolio of research-grade peptides. This segment provides more predictable revenue compared with large commercial contracts, which can be lumpy. However, catalog sales generally carry lower margins than specialized, late-stage commercial supply agreements. Management has emphasized a strategic focus on complex, high-value projects to support long-term profitability, as highlighted in the company’s Capital Markets Day materials from September 20, 2023.
Revenue Drivers and Product Pipeline
Revenue at Bachem is primarily generated through custom manufacturing contracts that supply clinical and commercial quantities of peptides. Contract volumes typically increase as a customer’s project advances from early-stage trials toward approval and market launch. This dynamic creates a lag between initial development work and peak revenue contributions. Consequently, the current sales mix reflects decisions made by pharma and biotech partners several years earlier.
A critical factor for future growth is the pipeline of projects in late-stage clinical development. In its 2023 annual report, dated March 19, 2024, Bachem indicated that a growing number of customer projects are advancing into later clinical phases. This progression can underpin future demand once approvals are granted. However, the timing of approvals depends on regulatory outcomes beyond Bachem’s control, and delays or discontinuations can affect near-term growth.
Oligonucleotides represent an additional growth area for the company. These molecules are used in advanced therapies, including antisense and RNA-based approaches that can silence or modify gene expression. Bachem has invested in capacity and capabilities in this segment, aiming to capture demand as more oligonucleotide drugs move through the pipeline. Because the field is still relatively young, revenue visibility in this area can be more limited. Nonetheless, successful product launches could add a meaningful incremental revenue stream over time.
Cost Structure and Margin Dynamics
On the cost side, plant utilization and chemical process efficiency are critical for margins. High utilization allows fixed costs to be spread across more output, while process optimization can reduce waste and improve yields. Bachem has communicated medium-term ambitions for higher profitability, supported by automation and expanded facilities. However, near-term margins can be under pressure when new capacity comes online and is not yet fully utilized, as noted in the company’s full-year 2023 presentation from March 19, 2024.
The interplay between capacity investments and utilization rates is a common challenge for CDMOs. When Bachem adds large-scale manufacturing capacity, it must balance the upfront capital expenditure with the time needed to fill that capacity with customer projects. Investors often monitor these metrics closely, as they directly impact earnings before interest, taxes, depreciation, and amortization (EBITDA) margins.
Recent Guidance Update and Market Context
In its spring 2025 investor communications, Bachem commented on its 2024 outlook and confirmed medium-term growth and margin targets. While the company did not provide a detailed numerical forecast, the reaffirmation signaled management’s confidence in the underlying demand drivers. The update comes against a backdrop of increasing interest in peptide-based drugs, driven by approvals in metabolic indications such as GLP-1 receptor agonists for diabetes and obesity, as well as ongoing research in oncology and rare diseases.
Bachem’s position as a Swiss-based manufacturer also brings currency considerations. Since the company trades in Swiss francs (CHF), fluctuations in the exchange rate can affect reported revenues for international clients and investors. This factor adds another layer of complexity to financial projections, particularly for US-based stakeholders.
For researchers and biohackers following the peptide field, Bachem’s activities are relevant because the company supplies the raw materials that underpin many preclinical and clinical studies. The availability of high-purity, GMP-grade peptides is essential for reproducible results in biological research. Bachem’s catalog business, in particular, provides a wide range of research peptides that scientists use to probe cellular pathways, develop assays, and test therapeutic hypotheses.
Conclusion
Bachem Holding AG occupies a specialized niche in the life-science supply chain, focusing on complex peptide and oligonucleotide manufacturing for pharmaceutical and biotech partners. Recent communications underscore that near-term dynamics can be influenced by project timing and plant utilization, while management continues to point to medium-term growth and profitability ambitions. For those studying the global CDMO and biotech supply ecosystem, the Swiss group exemplifies how innovation-driven demand, regulatory milestones, and capacity investments interact to shape the risk and return profile of a company.
Frequently Asked Questions
Q: What exactly does Bachem produce for the pharmaceutical industry?
A: Bachem develops and manufactures peptides and oligonucleotides that serve as active pharmaceutical ingredients (APIs) and research tools. Peptides are short chains of amino acids used in drugs for metabolic diseases, oncology, and rare conditions. Oligonucleotides are used in advanced therapies such as antisense and RNA-based approaches. The company offers services from early research quantities to commercial-scale production under Good Manufacturing Practice standards.
Q: How do Bachem’s revenue streams differ between custom manufacturing and catalog sales?
A: Custom manufacturing contracts involve long-term supply agreements for clinical and commercial quantities, typically generating higher margins but being lumpier in timing. Catalog sales provide a broad portfolio of research-grade peptides for academic and biotech labs, offering more predictable revenue but generally lower margins. Bachem emphasizes complex, high-value custom projects to support long-term profitability.
Q: What factors influence Bachem’s near-term financial performance?
A: Near-term performance is affected by plant utilization rates, chemical process efficiency, and the timing of customer projects advancing through clinical trials. New production capacity can pressure margins until fully utilized. Regulatory approvals for customer drugs also impact revenue, but these are outside Bachem’s control. Currency fluctuations between the Swiss franc and other currencies can further affect reported results.
Q: Why are oligonucleotides considered a growth area for Bachem?
A: Oligonucleotide-based therapies are gaining traction for conditions that are difficult to treat with small molecules or biologics, such as genetic disorders and certain cancers. Bachem has invested in dedicated manufacturing capacity and capabilities to serve this emerging pipeline. Although revenue visibility is limited due to the early stage of many programs, successful drug launches could provide a significant new revenue stream over the next decade.